ArticleBlood2012
Pretransplant MRD: the light is yellow, not red.
Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia.Bone marrow transplantation · 2017Article
- New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL.Bone marrow transplantation · 2014Review
- Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2014Article
- A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD).Bone marrow transplantation · 2014Article
- Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML.Bone marrow transplantation · 2013Article
- Minimal residual disease in acute myeloid leukaemia.Nature reviews. Clinical oncology · 2013Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the study reported in this issue of Blood by Leung et al, detectable minimal residual disease (MRD) before hematopoietic stem cell transplantation (HSCT) was found to be prognostic for outcome, but did not prevent cure for children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
Identifiers
22791775What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.